HCW Biologics is trading at $1.83, down 5.18%, in pre-market after its September 24 announcement of a $1.5 million private placement with an existing stockholder. - The offering comprises 903,614 units priced at $1.6599 each, consisting of pre-funded warrants and potential common warrants, raising dilution concerns. - Shares also fell 3.02% in the September 25 regular session. - Broader futures were lower, but the financing announcement is the clearest identified catalyst.